Acute Porphyria Workup
- Author: Richard E Frye, MD, PhD; Chief Editor: Max J Coppes, MD, PhD, MBA more...
Laboratory Studies
During acute episodes of porphyria, monitor electrolytes and serum osmolarity because hyponatremia and/or syndrome of inappropriate secretion of antidiuretic hormone can develop and cause seizures.
With the exception of aminolevulinic acid dehydratase (ALAD) deficiency, acute porphyrias can be diagnosed during acute episodes with 2 quick bedside tests to identify PBG. Both tests require porphobilinogen (PBG) levels 4 times the upper limit of normal. In either test, PBG reacts with para-dimethylaminobenzaldehyde (DMAB) to form a red compound. (Phenazopyridinium chloride, methyl red, and urosein may also turn the urine red under acidic conditions; these confounding factors can be excluded by testing a mixture of urine with hydrochloric acid. No simple tests are available to exclude compounds such as cascara sagrada, levomepromazine, methyldopa, antipyrine, phylloerythrinogen, indoles, and pyrrolic acids.)
Hoesch test is the simpler of the 2 tests and less prone to misinterpretation. For this test, mix 1-2 drops of urine with 1 mL of 6-mol/L hydrochloric acid (HCl) and 20 mg of DMAB. Immediate development of a cherry-red color at the top of the mixture indicates a positive result.
For the Watson-Schwartz test, mix 7.5 mL of a DMAB solution (10 mg/mL HCl) with 5 mL water. Mix 1 mL of the solution with 1 mL urine. Immediate formation of a red color suggests PBG excess. A positive result is confirmed by adding 2 mL saturated sodium acetate and then 3 mL chloroform to the positive mixture. After vigorous shaking, a red upper aqueous phase and a pink lower organic solution phase confirms a positive result.
Quantitative urine porphyrin levels vary. PBG levels vary approximately 20% when measured on a week-to-week basis and vary 25% when measured at a 10-week interval. This means that the the probability that the 2-fold increase in PBG concentration is actually related to the patient's disease is 80%. Porphyrin levels are elevated during an episode; hereditary coproporphyria (HCP) and variegate porphyria (VP) have identical urine porphyrin profiles and can be differentiated by examining stool porphyrins.
Table 3. Quantitative Urine Porphyrin Levels (Open Table in a new window)
| Level | ALAD Deficiency | Acute Intermittent Porphyria (AIP) | Congenital Erythropoietic Porphyria (CEP) and Porphyria Cutanea Tarda (PCT) | HCP and VP |
| ALA | Significantly increased | Significantly increased | Normal | Significantly increased |
| PBG | Increased | Significantly increased | Normal | Significantly increased |
| Uroporphyrin | Normal | Increased | Significantly increased | Increased |
| Coproporphyrin | Significantly increased | Increased | Increased | Significantly increased |
Comparing the relative increase in PBG levels during acute attacks with the asymptomatic period may be a more sensitive marker for acute neuroporphyria when compared with absolute PBG values. Patients with AIP, VP, or HCP have 2.3-50.5–fold increases in PBG levels during acute attacks.
ALAD deficiency can be diagnosed by detecting numerous fluorescent erythrocytes by microscopically examining the blood with a 100-W iodine-tungsten lamp.
Quantitative stool studies help differentiate between HCP and VP because these disorders have identical urine porphyrin profiles.
Table 4. Quantitative Stool Porphyrin levels (Open Table in a new window)
| Level | HCP | VP |
| Coproporphyrin | Significantly increased | Increased |
| Protoporphyrin | Increased | Significantly increased |
Despite their limitations, functional assays can help in diagnosing porphyria. ALAD and PBG enzymes are measured in erythrocytes. In ALAD deficiency, a functional deficiency of 25% or greater is diagnostic. This deficit is also detected in lead poisoning and in hereditary tyrosinemia. PBG deaminase is deficient in many patients with AIP; however, in 10% of patients with AIP, the enzyme defect is limited to the liver or housekeeping enzyme. Other assays (eg, test for coproporphyrinogen oxidase in lymphocytes) are available but unreliable.
Many genetic defects responsible for porphyria have been identified. In general, a large number of defects account for each porphyria. This finding limits the use of genetic testing to only 2 situations:
- If a genetic defect is known in an individual, his or her family members can be screened.
- Certain ethnic groups have a high prevalence of a particular mutation. For example, Dutch and Swedish Laplanders have a specific mutation in AIP, and many South African families have a specific mutation in VP.
Imaging Studies
MRI may reveal selective disturbance on white matter tracts that become myelinated and develop postnatally.
Gray matter and white matter in the brainstem and cerebellum appear to be preserved.
Other Tests
Electromyography and nerve conduction studies are nonspecific.
In patients with porphyrias, motor nerve conduction velocities are usually normal.
Partial antidromic block with significantly slowed conductance may be seen during asymptomatic periods in patients with VP or AIP.
Changes consistent with reinnervation may occur during the recovery of muscle weakness.
Histologic Findings
Peripheral nervous system
Histology shows axonal degeneration and patchy demyelination of motor axons, particularly short motor axons, which innervate the proximal and bulbar muscles. Axons are thin and irregular, with vacuolization, degeneration, and cellular infiltration. Neuronal loss and chromatolysis of the anterior horn cells may be secondary to retrograde degeneration. Chromatolysis of cranial nerve nuclei, commonly the dorsal vagus nucleus and autonomic nervous system ganglia (eg, celiac ganglion), may be observed.
CNS
Histologic evaluation may show chromatolysis and vacuolization of neurons and selective involvement of oligodendrocytes. Other findings include focal perivascular demyelination, reactive gliosis, and localized changes in the supraoptic and paraventricular nuclei of the hypothalamus.
Billoo AG, Lone SW. A family with acute intermittent porphyria. J Coll Physicians Surg Pak. May 2008;18(5):316-8. [Medline].
Ulbrichova D, Hrdinka M, Saudek V, Martasek P. Acute intermittent porphyria--impact of mutations found in the hydroxymethylbilane synthase gene on biochemical and enzymatic protein properties. FEBS J. Apr 2009;276(7):2106-15. [Medline].
Kuo HC, Huang CC, Chu CC, Lee MJ, Chuang WL, Wu CL, et al. Neurological complications of acute intermittent porphyria. Eur Neurol. 2011;66(5):247-52. [Medline].
Anyaegbu E, Goodman M, Ahn SY, Thangarajh M, Wong M, Shinawi M. Acute Intermittent Porphyria: A Diagnostic Challenge. J Child Neurol. Dec 21 2011;[Medline].
[Guideline] Finnish Medical Society Duodecim. Viral hepatitis. In: EBM Guidelines. Evidence-Based Medicine [Internet]. Helsinki, Finland: Wiley Interscience. John Wiley & Sons; 2008 Mar 10. [Full Text].
Aarsand AK, Petersen PH, Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem. Apr 2006;52(4):650-6. [Medline].
Anderson KE, Spitz IM, Sassa S, et al. Prevention of cyclical attacks of acute intermittent porphyria with a long-acting agonist of luteinizing hormone-releasing hormone. N Engl J Med. Sep 6 1984;311(10):643-5. [Medline].
Bylesjo I, Forsgren L, Lithner F, Boman K. Epidemiology and clinical characteristics of seizures in patients with acute intermittent porphyria. Epilepsia. Mar 1996;37(3):230-5. [Medline].
Delanty N, Vaughan CJ, French JA. Medical causes of seizures. Lancet. Aug 1 1998;352(9125):383-90. [Medline].
Estrov Y, Scaglia F, Bodamer OA. Psychiatric symptoms of inherited metabolic disease. J Inherit Metab Dis. Feb 2000;23(1):2-6. [Medline].
Gorchein A. Drug treatment in acute porphyria. Br J Clin Pharmacol. Nov 1997;44(5):427-34. [Medline].
Gordon N. The acute porphyrias. Brain Dev. Sep 1999;21(6):373-7. [Medline].
Gross U, Honcamp M, Daume E, et al. Hormonal oral contraceptives, urinary porphyrin excretion and porphyrias. Horm Metab Res. Aug 1995;27(8):379-83. [Medline].
Hift RJ, Meissner PN. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: Evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore). Jan 2005;84(1):48-60. [Medline].
Holroyd S, Seward RL. Psychotropic drugs in acute intermittent porphyria. Clin Pharmacol Ther. Sep 1999;66(3):323-5. [Medline].
Kappas A, Sassa S, Galbraith RA. The porphyrias. In: Scriver CR, et al, eds. The metabolic basis of inherited disease. New York, NY: McGraw-Hill; 1995:2103-2159.
Kauppinen R. Molecular diagnostics of acute intermittent porphyria. Expert Rev Mol Diagn. Mar 2004;4(2):243-9. [Medline].
Kauppinen R. Porphyrias. Lancet. Jan 15-21 2005;365(9455):241-52. [Medline].
Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology. Mar 1995;45(3 Pt 1):594-5. [Medline].
Logan GM, Weimer MK, Ellefson M, Pierach CA, Bloomer JR. Bile porphyrin analysis in the evaluation of variegate porphyria. N Engl J Med. May 16 1991;324(20):1408-11. [Medline].
Meyer UA, Schuurmans MM, Lindberg RL. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis. 1998;18(1):43-52. [Medline].
Onuki J, Chen Y, Teixeira PC, et al. Mitochondrial and nuclear DNA damage induced by 5-aminolevulinic acid. Arch Biochem Biophys. Dec 15 2004;432(2):178-87. [Medline].
Regan L, Gonsalves L, Tesar G. Acute intermittent porphyria. Psychosomatics. Nov-Dec 1999;40(6):521-3. [Medline].
Sadeh M, Blatt I, Martonovits G, et al. Treatment of porphyric convulsions with magnesium sulfate. Epilepsia. Sep-Oct 1991;32(5):712-5. [Medline].
Schoenfeld N, Mamet R. Individualized workup: a new approach to the biochemical diagnosis of acute attacks of neuroporphyria. Physiol Res. 2006;55 Suppl 2:S103-8. [Medline].
Solis C, Martinez-Bermejo A, Naidich TP, et al. Acute intermittent porphyria: studies of the severe homozygous dominant disease provides insights into the neurologic attacks in acute porphyrias. Arch Neurol. Nov 2004;61(11):1764-70. [Medline].
Soonawalla ZF, Orug T, Badminton MN, et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet. Feb 28 2004;363(9410):705-6. [Medline].
Suarez JI, Cohen ML, Larkin J, et al. Acute intermittent porphyria: clinicopathologic correlation. Report of a case and review of the literature. Neurology. Jun 1997;48(6):1678-83. [Medline].
Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. Jul 29 2000;356(9227):411-7. [Medline].
von und zu Fraunberg M, Pischik E, Udd L, Kauppinen R. Clinical and biochemical characteristics and genotype-phenotype correlation in 143 Finnish and Russian patients with acute intermittent porphyria. Medicine (Baltimore). Jan 2005;84(1):35-47. [Medline].
Yamamori I, Asai M, Tanaka F, et al. Prevention of premenstrual exacerbation of hereditary coproporphyria by gonadotropin-releasing hormone analogue. Intern Med. Apr 1999;38(4):365-8. [Medline].
| Type of Porphyria | Deficient Enzyme | Location | Inheritance Pattern | Band | |
| ALAD deficiency | ALAD | Cytosol | Autosomal recessive | 9q34 | |
| AIP | PBG deaminase | Cytosol | Autosomal dominant | 11q23 | |
| HCP | Coproporphyrinogen oxidase | Mitochondrial | Autosomal dominant | 3q12 | |
| VP | Protoporphyrinogen oxidase | Mitochondrial | Autosomal dominant | 1q22-23 |
| Type of Porphyria | Age of Onset | Incidence | Male-to-Female Ratio |
| ALAD deficiency | Mostly adolescence to young adulthood, but variable (2-63 y) | 6 cases total | 6:0 |
| AIP | After puberty (third decade) | General 0.01/1000 Sweden 1/1000 Finland 2/1000 France 0.3/1000 | M>F |
| HCP | Predominantly adulthood (youngest patient aged 4 y) | Japan 0.015/1000 Czech 0.015/1000 Israel 0.007/1000 Denmark 0.0005/1000 | 1:20 1:4 2:1 1:1 |
| VP | Heterozygous mutation: after puberty (fourth decade) Homozygous mutation (rare): childhood | South Africa 0.34/1000 | 1:1 |
| Level | ALAD Deficiency | Acute Intermittent Porphyria (AIP) | Congenital Erythropoietic Porphyria (CEP) and Porphyria Cutanea Tarda (PCT) | HCP and VP |
| ALA | Significantly increased | Significantly increased | Normal | Significantly increased |
| PBG | Increased | Significantly increased | Normal | Significantly increased |
| Uroporphyrin | Normal | Increased | Significantly increased | Increased |
| Coproporphyrin | Significantly increased | Increased | Increased | Significantly increased |
| Level | HCP | VP |
| Coproporphyrin | Significantly increased | Increased |
| Protoporphyrin | Increased | Significantly increased |

